When was Cellvation founded?

Cellvation was founded in 2016.

Where is Cellvation located?

Cellvation is headquartered in New York City, United States.

Is Cellvation a funded company?

Cellvation is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Cellvation rank among its competitors?

Cellvation ranks 3139th amongst 2855 active competitors, of which 987 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Karyopharm, which secured $30M in Mar, 2026.

Who are the top competitors of Cellvation?

Cellvation's top competitors include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Among them, Karyopharm secured the most recent funding round in March, 2026.

Cellvation - 2026 Company Profile, Team & Competitors

Company Details

Developing cellular therapeutics for traumatic brain injury treatment. This clinical-stage biopharmaceutical company focuses on creating innovative cellular therapies to address the unmet needs in traumatic brain injury (TBI) treatment. They are dedicated to advancing medical science through research and development, aiming to improve patient outcomes. Their pipeline includes novel therapies designed to target the underlying mechanisms of TBI. They are committed to scientific rigor and collaboration, working with experts to translate discoveries into effective treatments. Their approach involves regenerative medicine, seeking to restore function and enhance recovery for individuals affected by TBI.

Website: cellvation.com
Part Of

Key Metrics

Founded Year

2016

Location

New York City, United States

Stage

Unfunded

Ranked

3139^th among 3514 competitors

Similar Companies

Jazz Pharmaceuticals & 596 more

View Cellvation's full profile

Cellvation has not raised any funding rounds yet.

The founders of Cellvation is Frank Taffy.

Here are the details of Cellvation's key team members:

Frank Taffy: Co-Founder & CEO of Cellvation and founder of 1 other company.
Contact Info: 2 email addresses

View details of Cellvation's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Cellvation include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Here is the list of Top 10 competitors of Cellvation, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Gershon Capital & 10 others	78/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 27 others	77/100
4th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating human disease conditions	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
5th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
6th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
7th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
8th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
9th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
10th	Karyopharm 2008, Natick (United States), Public	Developer of small molecule drugs for the treatment of cancer and inflammatory disease	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
3139th	Cellvation 2016, New York City (United States), Unfunded	Developing cellular therapeutics for traumatic brain injury treatment	-	-	16/100